LRP1B expression in TCs stimulates the infiltration of CD4+ and CD8+ T cells and raises the ratio of CD86/CD163, which may be due to an increase in tumor immunogenicity to achieve immune activation and prevent disease progression. Here, CD86 is linked to neoplasm.